iTeos Therapeutics, Inc. (NASDAQ:ITOS) CEO Michel Detheux Sells 43,882 Shares

iTeos Therapeutics, Inc. (NASDAQ:ITOS - Get Free Report) CEO Michel Detheux sold 43,882 shares of the company's stock in a transaction that occurred on Monday, June 9th. The stock was sold at an average price of $10.03, for a total value of $440,136.46. Following the completion of the sale, the chief executive officer now owns 153,903 shares of the company's stock, valued at $1,543,647.09. This trade represents a 22.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Michel Detheux also recently made the following trade(s):

• On Tuesday, June 10th, Michel Detheux sold 43,883 shares of iTeos Therapeutics stock. The shares were sold at an average price of $10.02, for a total value of $439,707.66.
• On Monday, June 9th, Michel Detheux sold 8,400 shares of iTeos Therapeutics stock. The shares were sold at an average price of $10.03, for a total transaction of $84,252.00.
• On Friday, June 6th, Michel Detheux sold 43,882 shares of iTeos Therapeutics stock. The shares were sold at an average price of $10.21, for a total transaction of $448,035.22.
• On Friday, June 6th, Michel Detheux sold 8,400 shares of iTeos Therapeutics stock. The shares were sold at an average price of $10.21, for a total transaction of $85,764.00.
• On Wednesday, June 4th, Michel Detheux sold 43,883 shares of iTeos Therapeutics stock. The shares were sold at an average price of $10.10, for a total transaction of $443,218.30.
• On Wednesday, June 4th, Michel Detheux sold 8,400 shares of iTeos Therapeutics stock. The stock was sold at an average price of $10.10, for a total transaction of $84,840.00.

iTeos Therapeutics Trading Down 0.2%

NASDAQ ITOS traded down $0.02 on Thursday, hitting $9.98. 668,533 shares of the company's stock were exchanged, compared to its average volume of 667,026. The stock has a 50-day moving average of $7.64 and a 200-day moving average of $7.51. iTeos Therapeutics, Inc. has a 52 week low of $4.80 and a 52 week high of $18.13. The stock has a market cap of $381.97 million, a price-to-earnings ratio of -3.17 and a beta of 1.51.

iTeos Therapeutics (NASDAQ:ITOS - Get Free Report) last released its earnings results on Monday, April 28th. The company reported ($0.80) earnings per share for the quarter, topping the consensus estimate of ($0.94) by $0.14. As a group, analysts predict that iTeos Therapeutics, Inc. will post -3.49 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts have recently weighed in on the stock. Wells Fargo & Company reaffirmed an "equal weight" rating and set a $12.00 price objective (down previously from $13.00) on shares of iTeos Therapeutics in a report on Wednesday, May 28th. Leerink Partnrs downgraded iTeos Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, May 14th. Wedbush downgraded iTeos Therapeutics from an "outperform" rating to a "neutral" rating and lifted their price target for the company from $10.00 to $12.00 in a research note on Wednesday, May 28th. Leerink Partners reaffirmed a "market perform" rating and issued a $9.00 target price (down previously from $47.00) on shares of iTeos Therapeutics in a research report on Wednesday, May 14th. Finally, JPMorgan Chase & Co. cut iTeos Therapeutics from an "overweight" rating to a "neutral" rating and reduced their price target for the stock from $15.00 to $8.00 in a report on Tuesday, May 13th. Six investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat.com, iTeos Therapeutics presently has a consensus rating of "Hold" and an average price target of $15.86.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Balyasny Asset Management L.P. acquired a new position in shares of iTeos Therapeutics during the fourth quarter worth $218,000. Empowered Funds LLC increased its holdings in shares of iTeos Therapeutics by 5.0% during the fourth quarter. Empowered Funds LLC now owns 69,072 shares of the company's stock worth $530,000 after buying an additional 3,305 shares in the last quarter. BNP Paribas Financial Markets acquired a new position in shares of iTeos Therapeutics during the fourth quarter worth $461,000. Virtu Financial LLC increased its holdings in shares of iTeos Therapeutics by 84.3% during the fourth quarter. Virtu Financial LLC now owns 18,493 shares of the company's stock worth $142,000 after buying an additional 8,460 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd acquired a new position in shares of iTeos Therapeutics during the fourth quarter worth $142,000. 97.16% of the stock is currently owned by institutional investors and hedge funds.

iTeos Therapeutics Company Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.